{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:18:54Z","timestamp":1787843934278,"version":"build-2784847793"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor inhibitors (EGFRi) commonly cause papulopustular exanthemas that may compromise the success of cancer therapy. While tetracyclines are first\u2010line treatment, data on alternative systemic agents for refractory cases remain limited. This study compares the effectiveness and tolerability of isotretinoin and dapsone for managing tetracycline\u2010resistant EGFRi\u2013induced papulopustular eruptions in a tertiary dermatology service.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review was conducted of patients with EGFRi\u2010induced papulopustular eruptions treated with isotretinoin or dapsone between 2018 and 2024. Clinical data included demographics, malignancy type, EGFRi agent, eruption severity, prior therapies, Physician's Global Assessment, treatment outcomes, time to best response, adverse events, and EGFRi dose modification. Group comparisons used one\u2010way ANOVA and chi\u2010square\/Fisher's exact tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen patients were identified (8 isotretinoin, 8 dapsone). Baseline severity was higher in the isotretinoin group. Time to best response was shorter with isotretinoin (mean 14.9\u2009weeks) than dapsone (21.0\u2009weeks). Complete resolution occurred in 62.5% of isotretinoin\u2010treated patients and 50% of dapsone\u2010treated patients. Both agents were well tolerated, with only mild mucocutaneous effects in the isotretinoin group and mild anemia in one dapsone patient. Survival at follow\u2010up was higher among patients who continued EGFRi (with or without dose reduction) than among those who ceased treatment. No significant differences were observed between isotretinoin and dapsone in EGFRi dose modification patterns or overall response rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both isotretinoin and dapsone are effective, well\u2010tolerated options for managing tetracycline\u2010resistant EGFRi\u2010induced papulopustular eruptions. Isotretinoin showed a trend toward faster improvement, while ultimate response rates were similar. Maintaining EGFRi therapy, even at reduced doses, in conjunction with dermatology treatment was associated with superior dermatological outcomes and higher survival at follow\u2010up compared with cessation of EGFRi treatment, highlighting the importance of proactive dermatologic intervention to support oncologic treatment continuity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajd.70087","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:05:19Z","timestamp":1773122719000},"page":"288-293","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of Treatment Resistant\n                    <scp>EGFR<\/scp>\n                    Inhibitor\u2010Induced Papulopustular Exanthema With Isotretinoin and Dapsone"],"prefix":"10.1111","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8084-9232","authenticated-orcid":false,"given":"Ishana","family":"Dixit","sequence":"first","affiliation":[{"name":"Department of Dermatology Westmead Hospital  New South Wales Australia"},{"name":"Sydney Medical School, the University of Sydney  New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0478-3754","authenticated-orcid":false,"given":"Raquel Ruiz","family":"Araujo","sequence":"additional","affiliation":[{"name":"Department of Dermatology Westmead Hospital  New South Wales Australia"},{"name":"Sydney Medical School, the University of Sydney  New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-1564","authenticated-orcid":false,"given":"Pablo","family":"Fernandez\u2010Pe\u00f1as","sequence":"additional","affiliation":[{"name":"Department of Dermatology Westmead Hospital  New South Wales Australia"},{"name":"Sydney Medical School, the University of Sydney  New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.039"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.5070\/D327754366"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15412"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1211522"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.62.6.827"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.111"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)32039-2"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/2047\u2010783X\u201017\u20104"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0002\u20109440(10)62479\u20100"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.10.1725"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.013"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S427530"},{"issue":"10","key":"e_1_2_11_15_1","first-page":"1229","article-title":"Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors","volume":"9","author":"Pomerantz R. G.","year":"2010","journal-title":"Journal of Drugs in Dermatology: JDD"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi279"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3283474063"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12728"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13639"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70087","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajd.70087","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:33:39Z","timestamp":1787841219000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.70087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/ajd.70087"],"URL":"https:\/\/doi.org\/10.1111\/ajd.70087","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}